Experimental vaccine aims to boost immune attack on Hard-to-Treat cancers
Disease control
Ongoing
This study tests a new genetic vaccine called Nous-209, given together with the immunotherapy drug pembrolizumab (Keytruda), in adults with advanced MSI-H or dMMR solid tumors (colorectal, gastric, or gastro-esophageal junction cancers). The vaccine is designed to train the immun…
Phase: PHASE1, PHASE2 • Sponsor: Nouscom SRL • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC